Hepatitis virus C infection, adipokines and hepatic steato-fibrosis.

Inflammation and insulin resistance. J Clin Invest (2006) 18.76

Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest (2004) 13.42

Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A (2004) 2.54

Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis (2007) 2.41

Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26

Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol (2007) 1.75

Hepatitis C virus particles and lipoprotein metabolism. Semin Liver Dis (2005) 1.74

Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol (2005) 1.71

Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71

Targeting lipid metabolism in the treatment of hepatitis C virus infection. J Infect Dis (2008) 1.62

Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J (2004) 1.61

Recent concepts in non-alcoholic fatty liver disease. Diabet Med (2005) 1.54

The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol (2005) 1.49

An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol (2005) 1.46

Hepatitis C and steatosis: a reappraisal. J Viral Hepat (2006) 1.16

Impact of obesity on treatment of chronic hepatitis C. Hepatology (2006) 1.12

Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. J Infect Dis (2008) 1.07

Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab (2005) 1.06

Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatol Res (2005) 1.02

Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol (2006) 1.00

The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther (2007) 0.99

Nonalcoholic fatty liver disease. Rev Gastroenterol Mex (2005) 0.95

Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Gastroenterol Dietol (2006) 0.93

Non alcoholic fatty liver disease: a clinical approach and review. Can J Gastroenterol (2006) 0.92

Hepatitis C infection and diabetes. J Diabetes Complications (2006) 0.90

Combination of oxidative stress and steatosis is a risk factor for fibrosis in alcohol-drinking patients with chronic hepatitis C. Am J Gastroenterol (2008) 0.90

Signalling links in the liver: knitting SOCS with fat and inflammation. J Hepatol (2005) 0.87

Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy. J Gastroenterol Hepatol (2005) 0.87

High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. World J Gastroenterol (2006) 0.85

Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. Liver Int (2005) 0.84

Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C. Am J Gastroenterol (2005) 0.82

Acquired apolipoprotein B deficiency with chronic hepatitis C virus infection. Indian J Gastroenterol (2007) 0.80

Obesity-related non-alcoholic steatohepatitis and TGF-beta1 serum levels in relation to morbid obesity. Ann Hepatol (2004) 0.78

[Chronic hepatitis C--patients "difficult to treat"]. Przegl Epidemiol (2006) 0.77

Adipokines and insulin resistance in chronic hepatitis C. Hepatology (2007) 0.77

Gastric and colonic mantle cell lymphoma - incidental discovery. J Gastrointestin Liver Dis (2009) 0.79

Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C--a randomized trial. Nutr J (2013) 0.76

Development of a prognostic score for work disability in Romanian patients with ankylosing spondylitis. Disabil Rehabil (2014) 0.75